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Abstract Protein kinase D (PKD) is a novel serine/threonine
kinase structurally distinct from all protein kinase C (PKC)
isoforms but which like classic and novel PKCs is activated by
phorbol esters and diacylglycerol. This study investigated the
regulation of PKD in vascular smooth muscle cells (VSMC) by
physiological regulators of VSMC function and growth factors.
Treatment of rabbit aortic VSMC with phorbol ester, angio-
tensin II and PDGF-BB all stimulated PKD activity in a time-
and concentration-dependent manner in VSMC. The effect of
angiotensin II was particularly rapid and potent (maximum
stimulation within 1 min and at 0.5 nM). In contrast, the
maximum effect of PDGF-BB was obtained after 5 min. Other
factors, including basic FGF, IGF-I, IGF-II, endothelin-1 and
endothelin-2, had no effect on PKD activity in VSMC. These
results show for the first time that PKD activity is regulated in
VSMC, and is activated by the vasoconstrictor angiotensin II.
PKD may be an important mediator for the biological function(s)
of one or more PKC isoforms in VSMC and/or may represent a
component of a novel PKC-independent signalling pathway in
VSMC.
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1. Introduction
The activity of members of the protein kinase C (PKC)
family is regulated by diverse extracellular growth factors,
neurotransmitters, cytokines and hormones [1,2]. Classic and
novel isoforms of PKC are activated by the second messenger
diacylglycerol (DAG), generated through di¡erent pathways
including phospholipase C (PLC)-catalysed hydrolysis of
membrane inositol phospholipids. These PKCs are major cel-
lular binding sites for and are activated by tumour-promoting
phorbol esters [1^3]. PKCs are strongly implicated in a variety
of biological processes in mammalian cells [1^3]. In particular,
in arterial vascular smooth muscle cells (VSMC), PKC iso-
forms have been implicated in several biological functions
including both the negative [4,5] and positive [6] regulation
of cell proliferation, hypertrophy [7], the regulation of myosin
light chain function [8,9] and the contraction of several types
of arterial blood vessels [10^13]. Recently, a novel serine/
threonine protein kinase, called protein kinase D (PKD),
has been molecularly cloned which in common with conven-
tional and unusual subtypes of PKCs contains two cysteine-
rich, zinc-¢nger-like domains, binds phorbol ester and is acti-
vated by phorbol ester and DAG [14]. In other respects, how-
ever, PKD diverges from members of the PKC family and
represents a novel kinase subtype. Thus, unlike all eukaryotic
PKCs previously identi¢ed, PKD does not contain a typical
pseudosubstrate domain, but possesses a plekstrin homology
(PH) domain. The amino acid sequence of the catalytic do-
main of PKD also exhibits little homology to the catalytic
domains of PKC isoforms and is most closely related to
that of myosin light chain kinase (41% homology between
murine PKD and myosin light chain kinase of Dictyostelium)
[14]. A human kinase, termed PKCW, has been cloned, exhib-
its striking homology to PKD (92% overall), and probably
represents the human homologue of this enzyme [15].
Recent ¢ndings have implicated PKC isoforms in mediating
phorbol ester- and DAG-induced activation of PKD [16,17].
Little is known, however, concerning the regulation of PKD
in normal di¡erentiated mammalian cells. In the present paper
we investigated the occurrence and regulation of PKD in pri-
mary VSMC cultures. We report that PKD is rapidly acti-
vated in VSMC in response to biologically active phorbol
esters, the vasoconstrictor angiotensin II and the growth fac-
tor PDGF-BB. These results suggest that PKD may play a
role in intracellular signalling with implications for VSMC
function.
2. Materials and methods
2.1. Cell culture
VSMC were cultured from explants of rabbit aortic tunica media
obtained from 9-week-old New Zealand White rabbits as previously
described [18]. For experimental purposes, primary cultures of aortic
VSMC were rendered quiescent by incubation with DMEM contain-
ing 0.5% FCS for 40 h [18].
2.2. Immunoprecipitations
Cells were lysed at 4‡C in 1 ml of a solution containing 1% Triton
X-100, 50 mM Tris-HCl pH 7.5, 2 mM EDTA, 2 mM EGTA, 2 mM
dithiothreitol, 1 mM phenylmethylsulphonyl £uoride. Lysates were
clari¢ed by centrifugation at 15 000Ug for 10 min and then the super-
natants were used for immunoprecipitation. Immunoprecipitations
were routinely performed by incubating the lysates with 1 Wg/ml
anti-PKD polyclonal antibody (PA-1) overnight. Immunocomplexes
were collected by incubating the lysates with protein A-agarose beads
for a further 1 h.
2.3. Western blotting
After SDS-PAGE, proteins were transferred to Immobilon mem-
branes [18]. Membranes were blocked using 5% non-fat dried milk in
phosphate-bu¡ered saline, pH 7.2, and incubated for 3^5 h in phos-
phate-bu¡ered saline/0.05% Tween-20 containing antibody (1 Wg/ml)
as indicated. Immunoreactive bands were visualised either by chemi-
luminescence using HRP-conjugated anti-mouse or by anti-rabbit IgG
and ECL reagent.
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2.4. PKD autokinase assay
Anti-PKD immunoprecipitates were washed three times with lysis
bu¡er and twice with 30 mM Tris pH 7.4. The immunoprecipitates
were assayed for kinase activity by incubating them in 20 Wl of 30 mM
Tris pH 7.4 containing 10 WCi/ml [Q-32P]ATP, 100 WM ATP, 10 mM
MgCl2 for 10 min at 30‡C. The reaction was terminated by adding an
excess volume of lysis bu¡er at 4‡C. The samples were washed three
times in lysis bu¡er at 4‡C and then proteins were extracted in
2USDS-PAGE bu¡er at 95‡C for 5 min. The samples were resolved
by SDS-PAGE and then visualised by autoradiography. The auto-
phosphorylation of PKD was semi-quanti¢ed by scanning densitom-
etry of radiolabelled bands using an LKB Ultroscan XL densitometer.
2.5. Materials
PDGF-BB was obtained from RpD Systems. Angiotensin II and
phorbol 12-myristate 13-acetate (PMA) were from Sigma Chemical
Co., St. Louis, MO. Monoclonal PKCW antibody was from Trans-
duction Laboratories, Inc. Polyclonal antibody to PKD was raised
against a synthetic peptide corresponding to the COOH-terminal re-
gion of the predicted amino acid sequence of PKD, as described
previously [16]. Protein A-agarose, goat anti-rabbit IgG and goat
anti-mouse IgG were from Oncogene Science, Inc. ECL reagents,
HRP-conjugated anti-mouse IgG were from Amersham, UK. All oth-
er reagents used were of the purest grade available.
3. Results
Expression of PKD in primary cultures of rabbit aortic
VSMC was assessed by immunoprecipitation of PKD using
di¡erent amounts of a speci¢c polyclonal antibody directed
against murine PKD followed by Western blotting using a
second speci¢c monoclonal antibody raised against PKCW,
the human homologue of murine PKD. PKCW antibody rec-
ognised a major 100 kDa band in PKD immunoprecipitates
corresponding to the major 110 kDa PKD immunoreactive
species previously reported (results not shown).
Activation of PKD can be determined by autokinase assay
of PKD in PKD immunoprecipitates [16]. Lysates and PKD
immunoprecipitates were prepared from VSMC treated with
or without the biologically active phorbol ester PMA and
assayed for PKD autophosphorylation by incubation with
[Q-32P]ATP and Mg2. Kinase assay of control immunopreci-
pitates characteristically resulted in weak phosphorylation of
two bands of approximately 110 kDa. In some experiments,
phosphorylation of 110 kDa immunoreactive bands was not
detectable in control immunoprecipitates. Stimulation of
VSMC with PMA induced a striking increase in PKD auto-
phosphorylation (10-fold, n = 6). In kinase assays of immuno-
precipitates prepared from PMA-treated VSMC, a striking
increase occurred in phosphorylation of a major band migrat-
ing more slowly than the PKD-immunoreactive bands seen in
control immunoprecipitates. In some experiments, phospho-
rylation of additional bands in the Mr 110 000^120 000 range
was observed. The e¡ect of PMA was concentration-depend-
ent with a detectable increase at 5 nM and a maximum e¡ect
at 25 nM (Fig. 1). At a concentration of 100 nM, it was
consistently noted that the increase in PKD activity declined
relative to the e¡ect of 25 nM. As shown in Fig. 1, PMA-
induced PKD activation reached a maximum within 2 min
and was sustained at this level for up to 30 min.
Angiotensin II is a potent agonist for VSMC that induces
rapid GKq-mediated activation of L isoforms of PLC leading
to the formation of the second messengers Ins(1,4,5)P3 and
DAG which cause mobilisation of intracellular Ca2 and ac-
tivate classic and novel isoforms of PKC, respectively. As the
e¡ects of angiotensin II on PKD were not previously inves-
tigated in any cell type, we examined whether angiotensin II
regulates PKD in VSMC. Angiotensin II induced a striking
increase in the autokinase activity of PKD (Fig. 1). The e¡ect
of angiotensin II was very rapid with a maximum stimulation
achieved in 1 min which persisted for up to 30 min after its
addition (Fig. 1). Angiotensin II was also extremely potent in
inducing PKD autokinase activity with a maximum e¡ect at a
concentration as low as 0.5 nM (Fig. 1). Angiotensin II in-
duced an increase in PKD autophosphorylation approxi-
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Fig. 1. Stimulation of PKD activity in VSMC by phorbol ester and
angiotensin II. Top: VSMC were treated either with the indicated
concentrations of PMA or with 100 nM PMA for the indicated
times. PKD immunoprecipitates were prepared and assayed as de-
scribed in Section 2. The positions of molecular weight standards
(U1033) and phosphorylated and non-phosphorylated PKD forms
are indicated. The results shown are representative of six independ-
ent experiments. Bottom: VSMC were treated either for 10 min
with the indicated concentrations of angiotensin II (AII), or with
10 ng/ml angiotensin II for the times indicated. PKD immunopreci-
pitates were prepared and assayed as described in Section 2. The
positions of molecular weight standards (U1033) and phosphoryl-
ated and non-phosphorylated PKD forms are indicated. The results
shown are representative of three independent experiments.
Fig. 2. Stimulation of PKD activity in VSMC by PDGF-BB.
VSMC were treated for 10 min with the indicated concentrations of
PDGF-BB or with 25 ng/ml PDGF-BB for the times indicated,
PKD immunoprecipitates were prepared and kinase assays per-
formed as described. The results shown are representative of ¢ve in-
dependent experiments.
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mately equivalent to the e¡ect of PMA. Mean maximum in-
creases in autokinase PKD activity induced by angiotensin II
were 11-fold (n = 3) above control unstimulated levels.
PDGF-BB, a potent mitogen and chemoattractant for
VSMC, also increased PKD activity. Treatment of cells with
di¡erent concentrations of PDGF-BB followed by PKD im-
munoprecipitation and autokinase assay showed that PDGF-
BB caused a marked concentration-dependent increase in the
autophosphorylation of PKD (Fig. 2). The major phosphoryl-
ated band detected in PKD immunoprecipitates prepared
from PDGF-treated cells co-migrated exactly with the major
phosphorylated band in immunoprecipitates prepared in par-
allel PMA-treated cells. PDGF-BB-induced PKD autokinase
activity was detectable at 2.5 ng/ml and was maximum at
25 ng/ml. In contrast to the e¡ect of PDGF-BB, basic FGF
did not induce a signi¢cant increase in PKD activity in VSMC
(Fig. 2). Treatment of rabbit aortic VSMC with bFGF in-
duced a striking increase in activity of p42/p44 MAP kinases
as judged by Western blotting with an antibody speci¢c for
the activated form of MAP kinases indicating that other early
signalling events induced by bFGF were intact in these cells
(results not shown). The e¡ects of PMA and PDGF-BB were
also time-dependent. PDGF-BB-induced PKD activation
showed a detectable increase at 3 min, reached a near max-
imum level at 10 min and persisted above the control level for
up to 30 min after addition of the factor (Fig. 2). The mean
fold increases in PKD autokinase activity induced by PMA
and PDGF-BB were approximately 10-fold (n = 6) and 5-fold
(n = 5) above control unstimulated levels, respectively.
Several other polypeptide ligands for receptor protein tyro-
sine kinases and regulatory peptides known to act through
phospholipase CL-mediated phosphoinositol lipid hydrolysis
and generation of the second messenger DAG were also tested
for their e¡ect on PKD activity. In parallel cells and assays of
PKD activity, IGF-I, IGF-II and the vasoconstrictor agonists
endothelin-1 and endothelin-2 did not induce a signi¢cant
increase in PKD activity, while angiotensin II and PMA
both caused a striking activation of the enzyme (results not
shown).
4. Discussion
PKD is a novel serine/threonine protein kinase which is
regulated by phorbol esters and DAG, both activators of
conventional and unusual PKCs, but possesses several unique
features which distinguish it from all known members of the
PKC family, including an unrelated catalytic domain, the ab-
sence of a pseudosubstrate motif in its regulatory region, and
a PH domain between the second cysteine-rich domain and
the catalytic domain. At present the function or functions of
PKD in mammalian cells and tissues is unknown. As a ¢rst
step to understanding the function of PKD in cells of the
blood vessel wall, we have investigated the regulation of this
enzyme in VSMC. The results presented here demonstrate
that in primary cultures of aortic VSMC, phorbol esters, the
vasoconstrictor angiotensin II and PDGF-BB strikingly and
rapidly activate PKD. Activation of PKD was achieved at
concentrations of these factors which correspond closely to
those which produce biological responses in target cells, indi-
cating that activation of this kinase through receptors is medi-
ated through the same high-a⁄nity receptors. PDGF and sev-
eral peptides acting through G-protein-coupled receptors,
including bombesin, vasopressin, endothelin and bradykinin,
also activate PKD in the murine Swiss 3T3 cell line [19]. The
results presented here are the ¢rst report that PKD activity
can be regulated by the vasoconstrictor angiotensin II or is a
response to regulatory factors for VSMC.
The mechanism by which PKD is activated in VSMC is
unclear. It has previously been shown that PKD activation
in intact cells is blocked by selective inhibitors of PKC. In
in vitro assays, however, PKD is not susceptible to inhibition
by these inhibitors, suggesting that the e¡ects of PKC inhib-
itors in intact cells are indirect. Consistent with this interpre-
tation, expression of constitutively activated forms of certain
PKC isoforms induces activation of PKD expressed in COS-7
cells [16]. These results suggest that one mechanism by which
PKD is activated in intact cells is via one or more isoforms of
PKC. Since phorbol ester, PDGF-BB and angiotensin II all
activate PKC in VSMC, it is possible that PKC(s) may also
mediate PKD activation in these cells. Other polypeptide
growth factors and peptides known to activate PLC isoforms
and biologically active in rabbit aortic VSMC, including
bFGF, IGF-I and endothelins, failed to activate PKD. It is
plausible that selective activation of PKD may be determined
by agonist-speci¢c activation of particular PKC isotypes or
may be due to cell-type di¡erences in PKD regulation. The
role of PKC in mediating PKD activation and the identi¢ca-
tion of the PKC isotypes which may be responsible for PKD
activation in VSMC warrant further investigation.
The results revealed di¡erences between the responses to
PMA, PDGF-BB and angiotensin II. In particular, while
PDGF-BB was a weaker activator of PKD than phorbol es-
ter, angiotensin II induced an increase in PKD activity which
was equivalent to the e¡ect of PMA, at least as judged by
autokinase assay. Interestingly, the kinetics of PKD activation
also di¡ered. PDGF-BB-stimulated PKD activation was no-
ticeably slower than that induced by either PMA or angioten-
sin II. The basis for this slower activation by PDGF-BB is
unclear, but it was previously reported that in Swiss 3T3 cells,
PDGF-BB stimulation of mobilisation of intracellular Ca2
stores also exhibited slower kinetics compared to the e¡ect
of bombesin and other regulatory peptides acting through
G-protein-coupled receptors [20,21]. If PDGF-BB-induced
PKD activity is mediated via PKC, then the slower kinetics
of PKD activation by this factor might re£ect a slower acti-
vation of the phospholipase-CQ pathway leading to increased
DAG generation and inositol phosphate formation.
Members of the PKC family have been implicated in the
regulation of VSMC proliferation and in the responses of
VSMC to vasoconstrictors such as angiotensin II as well as
the contraction of several types of blood vessels and the con-
trol of myogenic tone [8^13,22,23]. Thus, the identi¢cation of
PKD activation as a common response to PDGF-BB, a po-
tent mitogen and chemoattractant for VSMC and the potent
vasoconstrictor angiotensin II may have implications for in-
tracellular signalling in both mitogenesis and contraction. It
was recently reported that PKD may be preferentially acti-
vated via the Ca2-independent PKCO isoform [16]. In this
context it is interesting that the O isoform has been implicated
in the control of contraction in neonatal rat cardiac myocytes
[24] and in Ca2-independent phenylephrine-induced contrac-
tion in ferret aorta [25]. The PKC isoforms mediating angio-
tensin II-induced contraction are unknown. Given that PKD
may be a downstream target for certain PKC isoforms, fur-
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ther investigation of PKD regulation in VSMC may prove to
be particularly valuable in elucidating PKC isoform-speci¢c
mechanisms of action and biological functions in these cells.
Regardless of whether PKD is a downstream e¡ector of PKCs
and/or is regulated through PKC-independent pathways, the
identi¢cation of PKD as a novel regulated kinase in VSMC is
likely to provide new insights into the mechanisms mediating
both PKC-dependent biological processes and the actions of
PDGF-BB and angiotensin II in VSMC.
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